Filing Flows › Procept BioRobotics (PRCT) › Guidance & outlook
Procept BioRobotics (PRCT) guidance and outlook
Procept BioRobotics (PRCT) reaffirmed its guidance on Nov 4, 2026: Revenue $390M–$410M for FY2026; Revenue +27% to +33% for FY2026; Gross margin 65% for FY2026; EBITDA $30.0M–$35.0M for FY2026. Procept BioRobotics' 10-Q filed Nov 4, 2026 makes 20 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $390M–$410M | reaffirmed |
| Revenue | FY2026 | +27% to +33% | reaffirmed |
| Gross margin | FY2026 | 65% | reaffirmed |
| EBITDA | FY2026 | $30.0M–$35.0M | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue.
- We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations for the foreseeable future.
- To penetrate these hospitals, we expect to continue to invest in our direct team of capital sales representatives, who are focused on driving system placement within hospitals by engaging with key surgeons and decision makers to educate them about the compelling value proposition of Aquablation therapy.
- As we increase our install base of robotic systems and upgrade our install base to the latest technology, we expect our revenue to increase as a result of the system sales and resulting increased utilization.
- Within each hospital we are initially focused on targeting urologists who perform resective procedures and converting their resective cases to Aquablation therapy.
- As urologists gain experience with Aquablation therapy and patients become increasingly aware of this surgical option, we expect to capture more surgical volumes and establish Aquablation therapy as the surgical standard of care.
- We believe our strong body of clinical evidence and support from key societies, supplemented by the momentum from Medicare coverage, have led to favorable coverage decisions from many large commercial payors and will continue to support sufficient levels of payor coverage.
- We also plan to leverage our treatment data and software development capabilities to integrate and further develop artificial intelligence and machine learning to enable computer-assisted anatomy recognition and improved treatment planning and personalization.
- We expect our revenue to increase in absolute dollars for the foreseeable future as we continue to focus on driving adoption of Aquablation therapy, and increased system utilization, though it may fluctuate from quarter to quarter.
- We expect that both our United States and international revenue will increase in the near term as we continue to expand the install base of our robotic systems and increase the related single-use disposable handpieces sold.
- We expect our increase in revenue in absolute dollars to be larger in the United States.
- We expect our cost of sales to increase in absolute dollars for the foreseeable future primarily as, and to the extent, our revenue grows, or we make additional investments in our manufacturing capabilities, though it may fluctuate from period to period.
Procept BioRobotics' latest quarter
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Procept BioRobotics raise or lower its guidance?
Procept BioRobotics (PRCT) reaffirmed its guidance on Nov 4, 2026: Revenue $390M–$410M for FY2026; Revenue +27% to +33% for FY2026; Gross margin 65% for FY2026; EBITDA $30.0M–$35.0M for FY2026.
What does Procept BioRobotics expect?
Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations for the foreseeable future. To penetrate these hospitals, we expect to continue to invest in our direct team of capital sales representatives, wh
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.